Trang chủ Our Doctors Dr Daniel Chan Boon Yeow

Dr Daniel Chan Boon Yeow

MBBS (Hons), MRCP (UK), FAMS (Medical Oncology), FRCP (UK)

Bác sĩ Ung bướu nội khoa

Make an Đặt lịch hẹn

Biography

Research

Languages spoken

Media

Memberships

Bài báo

“Tôi thực hành y tế chuyên biệt và dựa trên chứng cứ. Tôi xem mỗi bệnh nhân như là bạn hay người thân mà chúng tôi sẽ chăm sóc tốt nhất”

Biography

Tiểu sử

Bác sĩ Daniel Chan tốt nghiệp loại xuất sắc của chương trình tài năng khoa Y Đại học quốc gia Singapore (NUS) và tiếp tục được đào tạo nội khoa, nhận bằng MRCP (Anh) năm 2004. Ông tiếp tục được huấn luyện chuyên sâu về ung bướu tại Viện Ung bướu Đại học Quốc gia Singapore (Navonal University Cancer Institute). Ông đã hoàn thành năm học cuối quá trình thực tập của mình tại Đại học California, Los Angeles và Trung tâm Y khoa Cedars-Sinai. Ông có kiến thức dồi dào và kinh nghiệm sâu rộng trong điều trị ung bướu khi làm việc với các chuyên gia của UCLA và Cedars-Sinai theo chương trình hợp tác của NUH (Singapore) như Bác sĩ Ronald Natale (ung thư phổi), Bác sĩ Michael Lill (lympho), Bác sĩ Charles Forscher (sarcoma) and Bác sĩ Albert Lai (ung thư não). Ông cũng theo đuổi nghiên cứu chuyên sâu trong phòng thí nghiệm với Giáo sư nổi tiếng Phillip Koeffler về huyết học theo chương trình học bổng nước ngoài của hội nghiên cứu y khoa quốc gia (National Medical Research Council Overseas Fellowship)

Khi trở về nước, ông đảm nhiệm vai trò tư vấn cho Viện Ung bướu Đại học Quốc gia Singapore (National University Cancer Institute) và là giám đốc đào tạo bậc đại học (chuyên khoa ung bướu) tại Đại học Quốc gia Singapore. Ông cũng tham gia tích cực vào nghiên cứu điều trị ung bướu tại Cancer Science Institute Singapore và đã có một nghiên cứu mới từ NMRC về ung thư vú bộ ba âm tính. Ông là người đầu tiên ở Nam Á áp dụng liệu pháp miễn dịch PDL-1 (Pembrolizumab) trong điều trị lâm sàng vào tháng 10 năm 2014.

Các chuyên khoa: Ung thư vú, ung thư phổi, ung thư đại tràng, ung thư hạch, ung thư thần kinh và ung thư mô mềm.

Research

IL Believe

A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Diagnosis

Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma

Principal Investigator

Open for recruitment

Xem Trial

DeLLphi-306

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Diagnosis

Lung cancer

Open for recruitment

Xem Trial

Lunar-2

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Diagnosis

Lung cancer

Principal Investigator

Open for recruitment

Xem Trial

KRYSTAL-10

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Diagnosis

Colorectal cancer

Open for recruitment

Xem Trial

Bài báo

EGFR Mutation Detection in Plasma Cell-free DNA Correlates with Clinical Outcomes in Non-Small Cell Lung Cancer. J. Shi…Daniel Chan…M. Tan. Annals of Oncology 2017; 28:5: v460-v496.
Short course pembrolizumab in complete responders with advanced non-small cell lung cancer. Daniel Chan. J Clin Oncol 2017; 35; abstr e20537.
Genomic and Functional Characterizations of Phosphodiesterase 4D in Human Cancers. D Lin,…Daniel Chan, HP Koeffler. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(15):6109-6114.
A study on the prevalence of Her2 Genetic Heterogeneity and its impact on survival. J Ho, SC Lee, Daniel Chan, ES Koay. J Clin Oncol. 2013; 31: abstr 586.
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Daniel Chan, WL Yeo, M Tiemsim-Cordero M, et al. Invest New Drugs. 2010; 28(6): 859-65.

Media

30 March 2020 – The Straits Times: Lung cancer in young people
14 April 2020 – Lianhe Zaobao: Q&A lung cancer
17 May 2023 – CNA: What to know about lung cancer and its common gene mutations

Bài báo

EGFR Mutation Detection in Plasma Cell-free DNA Correlates with Clinical Outcomes in Non-Small Cell Lung Cancer. J. Shi…Daniel Chan…M. Tan. Annals of Oncology 2017; 28:5: v460-v496.
Short course pembrolizumab in complete responders with advanced non-small cell lung cancer. Daniel Chan. J Clin Oncol 2017; 35; abstr e20537.
Genomic and Functional Characterizations of Phosphodiesterase 4D in Human Cancers. D Lin,…Daniel Chan, HP Koeffler. Proceedings of the National Academy of Sciences of the United States of America 2013; 110(15):6109-6114.
A study on the prevalence of Her2 Genetic Heterogeneity and its impact on survival. J Ho, SC Lee, Daniel Chan, ES Koay. J Clin Oncol. 2013; 31: abstr 586.
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Daniel Chan, WL Yeo, M Tiemsim-Cordero M, et al. Invest New Drugs. 2010; 28(6): 859-65.

More information

Dr Daniel Chan Boon Yeow

MBBS (Hons), MRCP (UK), FAMS (Medical Oncology), FRCP (UK)

Biography

Research

Languages spoken

Media

Memberships

Bài báo

Biography

Tiểu sử

Research

IL Believe

Diagnosis

DeLLphi-306

Diagnosis

Lunar-2

Diagnosis

KRYSTAL-10

Diagnosis

Bài báo

Languages spoken

Media

Chi nhánh và thành viên

Bài báo

More information

Make an Đặt lịch hẹn

See all Doctors

Your nearest Icon centre

Tìm kiếm

Đường dẫn truy cập nhanh

Liên hệ với chúng tôi